[1]Tysnes OB, Storstein A. Epidemiology of
Parkinson’s disease [J]. J Neural Transm (Vienna), 2017,124(8):901-905.
[2]Beitz JM. Parkinson’ disease: a review[J]. Front Biosci (Schol Ed), 2014, (1):65-74.
[3]Sun X, Liang JQ, He JCh, et al. Research
progress of animal models of Parkinson’s disease
induced by neurotoxin[J].
Journal of Medical Research, 2020, 49(12):21-24.(in
Chinese)
孙雪, 梁建庆, 何建成, 等. 神经毒素诱导帕金森病动物模型的研究进展[J]. 医学研究杂志, 2020, 49(12):21-24.
[4]Wang TT, Chen ZhCh, Ye X, et al. Effect of
allopregnenolone on the dopaminergic neurons in the substantia nigra of
Parkinson’s disease mice[J]. Acta Anatomisica Sinica, 2020, 51(4):473-482.(in Chinese)
王彤彤, 陈治池, 叶鑫, 等. 别孕烯醇酮对帕金森病模型小鼠黑质多巴胺能神经元的影响及可能的分子机制[J]. 解剖学报, 2020, 51(4):473-482.
[5]Marogianni C, Sokratous M, Dardiotis E, et
al. Neurodegeneration and inflammation-an interesting interplay in Parkinson’s disease[J]. Int J
Mol Sci, 2020,21(22):8427.
[6]Bose A, Beal MF. Mitochondrial dysfunction
in Parkinson’s disease[J]. J Neurochem, 2016,139(1):216-231.
[7]Zhang L, Zhang L, Li Y, et al. The novel
dual GLP-1/GIP receptor agonist DA-CH5 is superior to single GLP-1 receptor
agonists in the MPTP model of Parkinson’s disease[J]. J Parkinsons Dis, 2020,10(2):523-542.
[8]Lin TK, Lin KJ, Lin HY, et al.
Glucagon-like peptide-1 receptor agonist ameliorates
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity through
enhancing mitophagy flux and reducing α-synuclein and
oxidative stress[J]. Front Mol
Neurosci, 2021,14:697440.
[9]Jalewa J, Sharma MK, Hlscher C. Novel incretin analogues improve autophagy and protect
from mitochondrial stress induced by rotenone in SH-SY5Y cells[J]. J Neurochem, 2016,139(1):55-67.
[10]Williams GP, Schonhoff AM, Jurkuvenaite
A, et al. CD4 T cells mediate brain inflammation and neurodegeneration in a
mouse model of Parkinson’s disease[J]. Brain, 2021,144(7):2047-2059.
[11]Hickman S, Izzy S, Sen P, et al.
Microglia in neurodegeneration[J]. Nat Neurosci, 2018,21(10):1359-1369.
[12]Siracusa R, Fusco R, Cuzzocrea S.
Astrocytes: role and functions in brain pathologies[J]. Front Pharmacol, 2019,10:1114.
[13]Diao X, Wang F, Becerra-Calixto A, et al.
Induced pluripotent stem cell-derived dopaminergic neurons from familial
Parkinson’s disease patients display α-synuclein pathology and abnormal
mitochondrial morphology[J].
Cells, 2021,10(9):2402.
[14]Cao B, Zhang Y, Chen J, et al.
Neuroprotective effects of liraglutide against inflammation through the
AMPK/NF-κB pathway in a mouse model of Parkinson’s disease[J]. Metab
Brain Dis, 2022,37(2):451-462.
[15]Monzio Compagnoni G, Di Fonzo A, Corti S,
et al. The role of mitochondria in neurodegenerative diseases: the lesson from
Alzheimer’s disease and Parkinson’s disease[J]. Mol
Neurobiol, 2020,57(7):2959-2980.
[16]Richter V, Singh AP, Kvansakul M, et al.
Splitting up the powerhouse: structural insights into the mechanism of
mitochondrial fission[J]. Cell
Mol Life Sci, 2015,72(19):3695-3707.
[17]Feng ST, Wang ZZ, Yuan YH, et al. Dynaminrelated protein 1: a protein critical for mitochondrial fission,
mitophagy, and neuronal death in Parkinson’s disease[J]. Pharmacol Res, 2020,151:104553.
[18]Lee JY, Nagano Y, Taylor JP, et al.
Disease-causing mutations in parkin impair mitochondrial ubiquitination,
aggregation, and HDAC6-dependent mitophagy[J]. J Cell Biol, 2010,189(4):671-679.
[19]Pham AH, Meng S, Chu QN, et al. Loss of
Mfn2 results in progressive, retrograde degeneration of dopaminergic neurons in
the nigrostriatal circuit[J].
Hum Mol Genet, 2012,21(22):4817-4826.
[20]Zhao F, Wang W, Wang C, et al. Mfn2
protects dopaminergic neurons exposed to paraquat both in vitro and in vivo:
implications for idiopathic Parkinson’s disease[J]. Biochim Biophys Acta Mol Basis Dis,
2017,1863(6):1359-1370.
[21]Hu Z, Mao C, Wang H, et al. CHIP protects
against MPP(+)/MPTP-induced damage by regulating Drp1 in two models of
Parkinson’s disease[J]. Aging (Albany NY), 2021,13(1):1458-1472.
[22]Wu P, Dong Y, Chen J, et al. Liraglutide
regulates mitochondrial quality control system through PGC-1α in a mouse model of Parkinson’s disease[J]. Neurotox Res, 2022,40(1):286-297.
[23]Jassim AH, Inman DM, Mitchell CH.
Crosstalk between dysfunctional mitochondria and inflammation in glaucomatous
neurodegeneration[J]. Front
Pharmacol, 2021,12:699623.
[24]Voloboueva LA, Emery JF, Sun X, et al.
Inflammatory response of microglial BV-2 cells includes a glycolytic shift and
is modulated by mitochondrial glucose-regulated protein 75/mortalin[J]. FEBS Lett, 2013,587(6):756-762.
[25]Misawa T, Takahama M, Kozaki T, et al.
Microtubule-driven spatial arrangement of mitochondria promotes activation of
the NLRP3 inflammasome[J]. Nat
Immunol, 2013,14(5):454-460.
[26]Ongnok B, Maneechote C, Chunchai T, et
al. Modulation of mitochondrial dynamics rescues cognitive function in rats
with ’doxorubicin-induced chemobrain via ’ mitigation of mitochondrial dysfunction and neuroinflammation[J]. FEBS J, 2022,289(20):6435-6455.
[27]Stavropoulos
F, Sargiannidou I, Potamiti L, et al. Aberrant mitochondrial dynamics and
exacerbated response to neuroinflammation in a novel mouse model of CMT2A[J]. Int J Mol Sci, 2021,22(21):11569.
|